Advanced search
Publication Cover
Journal of Obstetrics and Gynaecology Volume 43, 2023 - Issue 1
Submit an article Journal homepage
1,270
Views
1
CrossRef citations to date
0
Altmetric
Case Reports

HER2 amplification in Uterine carcinosarcoma after tamoxifen therapy: a case report

Fuqiang ZhengDepartment of Oncology, First Affiliated Hospital of Hunan Normal University (Hunan Provincial People’s Hospital), Changsha, ChinaView further author information
&
Xiaocai TianDepartment of Oncology, First Affiliated Hospital of Hunan Normal University (Hunan Provincial People’s Hospital), Changsha, ChinaCorrespondence[email protected]
View further author information
Article: 2125301 | Published online: 23 Sep 2022

References

  • Early Breast Cancer Trialists’ Collaborative Group. 1998. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467.
  • Jones ME, Van Leeuwen FE, Hoogendoorn WE, Mourits MJ, Hollema H, Van Boven H, et al. 2012. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Research 14:R91.
  • Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, et al. 2002. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. International Journal of Gynecological Cancer 12:496–500.
  • Matsuo K, Ross MS, Bush SH, Yunokawa M, Blake EA, Takano T, et al. 2017. Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. Gynecologic Oncology 144:329–335.
  • Moukarzel LA, Ferrando L, Da Cruz Paula A, Brown DN, Geyer FC, Pareja F, et al. 2021. The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. Molecular Oncology 15:1024–1039.
  • Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, et al. 2015. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clinical and Experimental Metastasis 32:29–38.
  • Pezzicoli G, Moscaritolo F, Silvestris E, Silvestris F, Cormio G, Porta C, D’oronzo S. 2021. Uterine carcinosarcoma: an overview. Critical Reviews in Oncology/Hematology 163:103369.
  • Raspollini MR, Susini T, Amunni G, Paglierani M, Taddei A, Marchionni M, et al. 2005. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? Gynecologic Oncology 96:159–167.
  • Rottmann D, Snir OL, Wu X, Wong S, Hui P, Santin AD, Buza N. 2020. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. Modern Pathology 33:118–127.
  • Sawada M, Tsuda H, Kimura M, Okamoto S, Kita T, Kasamatsu T, et al. 2003. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Science 94:986–991.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.